EDMONTON, Alberta, Feb. 27, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") is pleased to announce that its CEO, Dr. Robert Foster, has been invited to speak at the BioPartnering North America ("BPN") 2012 conference. Dr. Foster will participate in a BPN workshop entitled "Need + Innovation = Opportunity" to be held on Tuesday, February 28, 2012 at 4:00 PM PT at the Vancouver Convention Center.
"We are delighted to be given this opportunity to share with a global audience the continued progress of our voclosporin program," commented Dr. Foster. "In addition, we will be meeting individually with several leading international pharmaceutical and biotechnology companies at the conference to discuss possible partnership and licensing opportunities."
Now in its 10th year of partnering & dealmaking, BPN is produced by TVG & LifeSciences British Columbia, and hosted by BIOTECanada and BioAlberta. The conference brings together senior executives from investment firms, major pharmaceutical companies, academic institutions and biotechnology companies of every size from around the globe.
About Isotechnika Pharma Inc.
Isotechnika Pharma Inc. is a biopharmaceutical company focused on the discovery and development of immunomodulating therapeutics designed to offer key safety advantages over currently available treatments. Its lead drug, voclosporin, is a calcineurin inhibitor, and is targeted at the estimated US$3.0 billion market for this class of immunosuppressants. Isotechnika Pharma Inc. trades on the Toronto Stock Exchange under the symbol "ISA". More information on Isotechnika Pharma can be found at www.isotechnika.com or www.sedar.com.
We seek Safe Harbour.